Skip to content

Shattuck Labs, Inc. STTK Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Amgen logo
AmgenAMGN
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
Arcus Biosciences logo
Arcus BiosciencesRCUS

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s unrealized gains on investments?
Shattuck Labs, Inc. (STTK) reported unrealized gains on investments of $0 in Q1 2026.
What is the long-term trend for Shattuck Labs, Inc.'s unrealized gains on investments?
Over 5 years (2020 to 2025), Shattuck Labs, Inc.'s unrealized gains on investments has grown at a -37.5% compound annual growth rate (CAGR), from -$63K to $6K.
What does unrealized gains on investments mean?
This represents the cumulative increase in the fair value of investment securities held by the company that have not yet been sold. It reflects the paper profit generated from the company's treasury or strategic investment portfolio. This metric provides insight into the performance of the company's non-operating asset management.